AtriCure Inc

ATRC

Equity

ISIN US04963C2098 / Valor 2134051

NASDAQ (2024-09-18)

USD 27.99-0.29%

AtriCure Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

AtriCure Inc. is a prominent medical device company specializing in the development and provision of advanced technologies aimed at the treatment of Atrial Fibrillation (Afib) and related cardiac conditions. The company has established itself as a trusted partner for electrophysiologists and cardiothoracic surgeons globally, offering a range of products designed to address complex cardiac cases. Among its notable innovations is the Isolator® Synergy™ Ablation System, distinguished as the first device of its kind to receive FDA approval for the treatment of persistent Afib. Additionally, AtriCure's AtriClip Left Atrial Appendage Exclusion System stands out as the most extensively utilized device worldwide for left atrial appendage management. The company also offers the Hybrid AF™ Therapy, a minimally invasive approach catering to patients with long-standing persistent Afib, and the cryoICE cryoSPHERE® probe, which is approved for the temporary ablation of peripheral nerves to alleviate pain during cardiac and thoracic surgeries. AtriCure is committed to advancing the field of cardiac care through continuous investment in innovation, clinical science, and educational initiatives aimed at enhancing patient outcomes globally.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

AtriCure Inc. reported worldwide revenue of $116.3 million for the second quarter of 2024, marking a 15.2% increase year over year. This growth was driven by strong adoption of their products globally, particularly in the U.S. pain management and international franchises.

U.S. Revenue

In the United States, AtriCure Inc. achieved revenue of $95.5 million for the second quarter of 2024, an increase of $10.6 million or 12.5% compared to the same period in 2023. Key product lines contributing to this growth included cryoSPHERE® probes for post-operative pain management and the AtriClip® Flex·V® device in appendage management.

International Revenue

International revenue for AtriCure Inc. in the second quarter of 2024 was $20.7 million, reflecting a significant increase of $4.7 million or 29.4% year over year. This growth was realized across all franchises and most major geographic regions.

Gross Profit and Margin

AtriCure Inc. reported a gross profit of $86.8 million for the second quarter of 2024, compared to $77.1 million for the same period in 2023. However, the gross margin decreased by 168 basis points to 74.7%, due to less favorable geographic and product mix, as well as increased product costs.

Financial Guidance

AtriCure Inc. has updated its full-year 2024 revenue guidance to approximately $456 million to $461 million, reflecting a growth of around 15% at the midpoint. The company also expects full-year 2024 Adjusted EBITDA to be in the range of $26 million to $29 million, representing a 34% to 49% increase over 2023.

Summarized from source with an LLMView Source

Key figures

-35.6%1Y

-63.5%3Y

8.53%5Y

Performance

50.5%1Y

47.8%3Y

46.3%5Y

Volatility